Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Ezekowitz

Showing results (111-120 of 187) with videos related to

Pageof 19
Sort By:
Lancet (London, England)|December 10, 2013
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsChristian T Ruff, Robert P Giugliano, Eugene Braunwald, et al.
Circulation|August 30, 2016
Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial FibrillationJonas Oldgren, Ziad Hijazi, Johan Lindbäck, et al.
Journal of the American College of Cardiology|July 2, 2011
Percutaneous tricuspid valve replacement in congenital and acquired heart diseasePhilip A Roberts, Younes Boudjemline, John P Cheatham, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|March 6, 2016
Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillationMichael D Ezekowitz, John Eikelboom, Jonas Oldgren, et al.
Journal of Thrombosis and Thrombolysis|August 6, 2005
The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481--the Home INR Study (THINRS)David B Matchar, Alan K Jacobson, Robert G Edson, et al.
European Heart Journal|October 26, 2017
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk scoreZiad Hijazi, Jonas Oldgren, Johan Lindbäck, et al.
American Heart Journal|September 29, 2014
Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)Emily C O'Brien, DaJuanicia N Simon, Larry A Allen, et al.
Lancet (London, England)|April 9, 2016
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation studyZiad Hijazi, Jonas Oldgren, Johan Lindbäck, et al.
Journal of the American College of Cardiology|December 17, 2015
Reply: Anticoagulant-Related NephropathyMichael Böhm, Michael D Ezekowitz, Stuart J Connolly, et al.
Circulation|February 20, 2008
ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm SocietyN A Mark Estes, Jonathan L Halperin, Hugh Calkins, et al.
Pageof 19

Showing results (111-120 of 187) with videos related to

Sort By:
Pageof 19
Lancet (London, England)|December 10, 2013
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsChristian T Ruff, Robert P Giugliano, Eugene Braunwald, et al.
Circulation|August 30, 2016
Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial FibrillationJonas Oldgren, Ziad Hijazi, Johan Lindbäck, et al.
Journal of the American College of Cardiology|July 2, 2011
Percutaneous tricuspid valve replacement in congenital and acquired heart diseasePhilip A Roberts, Younes Boudjemline, John P Cheatham, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|March 6, 2016
Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillationMichael D Ezekowitz, John Eikelboom, Jonas Oldgren, et al.
Journal of Thrombosis and Thrombolysis|August 6, 2005
The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481--the Home INR Study (THINRS)David B Matchar, Alan K Jacobson, Robert G Edson, et al.
European Heart Journal|October 26, 2017
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk scoreZiad Hijazi, Jonas Oldgren, Johan Lindbäck, et al.
American Heart Journal|September 29, 2014
Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)Emily C O'Brien, DaJuanicia N Simon, Larry A Allen, et al.
Lancet (London, England)|April 9, 2016
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation studyZiad Hijazi, Jonas Oldgren, Johan Lindbäck, et al.
Journal of the American College of Cardiology|December 17, 2015
Reply: Anticoagulant-Related NephropathyMichael Böhm, Michael D Ezekowitz, Stuart J Connolly, et al.
Circulation|February 20, 2008
ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm SocietyN A Mark Estes, Jonathan L Halperin, Hugh Calkins, et al.
Pageof 19